Associate Professor
Oncology
Dr. Karen L. Reckamp, MD
|
|
Give Review
Karen Reckamp works in the field of Oncology. She studied medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care She over the years received 1 awards: "Super Doctor". Dr. Karen L. Reckamp is a published physician. She has 61 publications published. The most current publication "NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016." She accepts Medicare.
Publications
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
- Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures.
- Phase I study of the halichondrin B Analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
- Future of ALK inhibition in non-small-cell lung Cancer.
- PGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC.
- The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated Cancers.
- A phase 2 trial of dacomitinib (PF-00299804), an Oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cel...
- EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung.
- Sexuality, lung Cancer, and the older adult: an unlikely trio?
- Phosphatidylinositol-3-kinase pathway.
- Novel mechanisms and targets: misCellaneous agents.
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib.
- Combination chemotherapy for older adults with advanced non-small-cell lung Cancer.
- Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.
- Non-small cell lung Cancer in the elderly: defining treatment options.
- The role of targeting mammalian target of rapamycin in lung Cancer.
- Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.
- Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung Cancer is associated with a low baseline matrix metalloproteinase-9 and a decline ...
- Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to Systemic IL-2 therapy.
- A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung Cancer.
- Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell Carcinoma.
- ProstaGlandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth fac...
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- Malignant pleural mesothelioma. Clinical practice guidelines in oncology.
- A phase I study of bortezomib and temozolomide in patients with advanced solid Tumors.
- Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-Cell...
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Targeting STAT3 in adoptively transferred T Cells promotes their in vivo expansion and antitumor effects.
- Consistency of a two clinical site sample collection: a proteomics study.
- City of Hope Cancer Center hematology-oncology fellowship and hematopoietic stem cell transplantation fellowship.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung Cancer: a California Cancer consortium trial.
- An interdisciplinary care approach for integration of palliative care in lung Cancer.
- Summary of selected presentations from the 8th annual targeted therapy in lung Cancer symposium.
- Identification of five candidate lung Cancer biomarkers by proteomics analysis of conditioned media of four lung Cancer cell lines.
- Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small Cell...
- Molecular origins of lung Cancer: prospects for personalized prevention and therapy.
- STAT3: a target to enhance antitumor immune response.
- Targeted therapies for non-small cell lung Cancer: an evolving landscape.
- Non-small cell lung Cancer.
- PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung Cancer.
- Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T Cells.
- Akt inhibitors in clinical development for the treatment of Cancer.
- Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung Cancer.
- Thymic malignancies.
- A multiparametric serum kallikrein panel for diagnosis of non-small cell lung Carcinoma.
- Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell Carcinoma metastasis.
- PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic Cells.
- Tumor cyclooxygenase-2/prostaGlandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
- Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.
- ProstaGlandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells.
- Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung Cancer.
- The role of CXCR2/CXCR2 ligand biological axis in renal cell Carcinoma.
- Radiofrequency ablation in lung Cancer: promising results in safety and efficacy.
- The potential and rationale for COX-2 inhibitors in lung Cancer.
- Inflammation and Lung carcinogenesis: applying findings in prevention and treatment.
- Chemokines as therapeutic targets in renal cell Carcinoma.
- CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung Cancer.
- Management of non-small-cell lung Cancer in the older adult.
- Myeloid Clusters Are Associated with a Pro-Metastatic Environment and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer.
Schools
University of Chicago Pritzker School of Medicine
BarnesJewish Hospital Washington University
David Geffen School Of Medicine At UCLA
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Thoracic Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
UCLA Medical Center -
Washington University - Barnes-Jewish Hospital -
University of Chicago Pritzker School of Medicine
Hospital
-
City of Hope's Helford Clinical Research Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Przemyslaw Twardowski, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Frederic Grannis, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Dan J. Raz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jana Portnow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanne Mortimer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jae Y. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thehang H. Luu, MD
This Doctor is OpenDoctor Recommended.
|